MED1 IDR deacetylation controls stress responsive genes through RNA Pol II recruitment.
1/5 보강
Cells fine-tune gene expression in response to cellular stress, a process critical for tumorigenesis.
APA
Lin R, Mo Y, et al. (2026). MED1 IDR deacetylation controls stress responsive genes through RNA Pol II recruitment.. Nature chemical biology, 22(3), 501-513. https://doi.org/10.1038/s41589-025-02035-7
MLA
Lin R, et al.. "MED1 IDR deacetylation controls stress responsive genes through RNA Pol II recruitment.." Nature chemical biology, vol. 22, no. 3, 2026, pp. 501-513.
PMID
41131199
Abstract
Cells fine-tune gene expression in response to cellular stress, a process critical for tumorigenesis. However, mechanisms governing stress-responsive transcription remain incompletely understood. This study shows that the MED1 subunit of the Mediator coactivator complex is acetylated in its intrinsically disordered region (IDR). Under stress, SIRT1 associates with the super elongation complex to deacetylate MED1 in promoter-proximal regions. The deacetylated (or acetylation-defective mutant) MED1 amplified stress-activated cytoprotective genes and rescued stress-suppressed growth-supportive genes in estrogen-receptor-positive breast cancer (ER BC) cells. Mechanistically, deacetylated MED1 promotes chromatin incorporation of RNA polymerase II (Pol II) through IDR-mediated interactions. Functionally, ER BC cells with deacetylated MED1 exhibit faster growth and enhanced stress resistance in culture and in an orthotopic mouse model. These findings advance our understanding of Pol II regulation under cellular stress and potentially suggest therapeutic strategies targeting oncogenic transcription driven by MED1 and Mediator.
MeSH Terms
Mediator Complex Subunit 1; RNA Polymerase II; Humans; Animals; Acetylation; Mice; Female; Stress, Physiological; Breast Neoplasms; Cell Line, Tumor; Sirtuin 1; Gene Expression Regulation, Neoplastic
같은 제1저자의 인용 많은 논문 (5)
- A foundation model for predicting outcomes of neoadjuvant chemotherapy in breast cancer.
- Overcoming STING-Driven Immunosuppression with a Bifunctional STING Agonist/PD-L1 Inhibitor for Enhanced Antitumor Immunity.
- Breaking barriers: Extracellular vesicles as dual-agents in diagnosing and treating brain metastasis.
- Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target via multi-omics machine learning integration.
- The role of histone acetyltransferases in tumorigenesis and their therapeutic potential: A review.